Skinny Label Lessons from GSK v. Teva Video

Summary

This video highlights the risk that a generic drug company may be found liable for patent infringement even when its FDA drug approval is based on a so-called skinny label. This video discusses the Federal Circuit's decision in Glaxosmithkline LLC v. Teva Pharm. USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021) and the evidence the court relied upon in finding induced infringement.